Skip to main content

Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia

  • Protocol
  • First Online:
Pancreatic Cancer

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1882))

Abstract

Cachexia, a complex metabolic syndrome, is characterized by involuntary weight loss along with muscle wasting and fat depletion leading to poor quality of life of patients. About 80% of pancreatic cancer patients exhibit cachectic phenotype at the time of diagnosis. Here, we present the several molecular and physiological parameters, which we utilize to study the pancreatic cancer-induced cachexia in in vitro models and preclinical mice models of pancreatic cancer. We have described myotube and adipocyte-based in vitro models of muscle and fat wasting, including methods of cell culture, differentiation, and treatment with cancer cell-conditioned medium. Furthermore, we have explained the methods of evaluation of key cachectic markers for muscles. Next, we have detailed the orthotopic implantation mouse models of pancreatic cancer and evaluation of different physiological parameters, including body weight, food intake, body composition analysis, glucose tolerance test, insulin resistance test, grip strength measurement, and rotarod performance test. We have also explained morphological parameters and molecular markers to evaluate the muscle wasting in pancreatic cancer-induced cachexia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2:862–871

    Article  CAS  Google Scholar 

  2. Lok C (2015) Cachexia: The last illness. Nature 528:182–183

    Article  CAS  Google Scholar 

  3. Johns N, Stephens NA, Fearon KC (2013) Muscle wasting in cancer. Int J Biochem Cell Biol 45:2215–2229

    Article  CAS  Google Scholar 

  4. Tuca A, Jimenez-Fonseca P, Gascon P (2013) Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol 88:625–636

    Article  Google Scholar 

  5. Argiles JM, Fontes-Oliveira CC, Toledo M, Lopez-Soriano FJ, Busquets S (2014) Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 5:279–286

    Article  Google Scholar 

  6. Shukla SK, Gunda V, Abrego J, Haridas D, Mishra A, Souchek J et al (2015) MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget 6:19118–19131

    PubMed  PubMed Central  Google Scholar 

  7. Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E et al (2017) MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell 32:71–87 e7

    Article  CAS  Google Scholar 

  8. Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J et al (2017) De novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer. Cancer Res 77:5503–5517

    Article  CAS  Google Scholar 

  9. Gunda V, Souchek J, Abrego J, Shukla SK, Goode GD, Vernucci E et al (2017) MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. Clin Cancer Res 23:5881–5891

    Article  CAS  Google Scholar 

  10. Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X et al (2012) MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A 109:13787–13792

    Article  CAS  Google Scholar 

  11. Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P et al (2014) Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab 2:18

    Article  Google Scholar 

  12. Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Souchek J et al (2015) Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget 6:41146–41161

    PubMed  PubMed Central  Google Scholar 

  13. Kotler DP (2000) Cachexia. Ann Intern Med 133:622–634

    Article  CAS  Google Scholar 

  14. Shukla SK, Kumar V (2012) Hepatitis B virus X protein and c-Myc cooperate in the upregulation of ribosome biogenesis and in cellular transformation. FEBS J 279:3859–3871

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pankaj K. Singh .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Shukla, S.K., Dasgupta, A., Mulder, S.E., Singh, P.K. (2019). Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. In: Su, G. (eds) Pancreatic Cancer. Methods in Molecular Biology, vol 1882. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8879-2_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8879-2_28

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-8878-5

  • Online ISBN: 978-1-4939-8879-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics